CPIC website (https://www.pharmgkb.org/guidelines) lists 35 entries for drugs in several therapeutic classes, corresponding to 20 original or updated guidelines. For example, azathioprine, mercaptopurine and thioguanine are listed separately, but comprised in a single guideline for thiopurines.
We carried out a literature search to assess the extent of PGx research and implementation in Brazil, focusing on the drugs and pharmacogenes included in the CPIC guidelines. The current-day Brazilian population, in excess of 200 million people, is highly heterogeneous as a consequence of five centuries of admixture between Native Americans, Europeans and Africans. [4] [5] [6] This heterogeneity poses challenges to extrapolation of PGx data from other populations to Brazilians 7-9 and possibly for adoption of CPIC guidelines in Brazil.
| METHODS
Data from two sources were used to prepare this review: firstly, PubMed, using as search terms the drug(s) and gene(s) in each CPIC guideline plus "Brazil*" (eg clopidogrel AND CYP2C9 AND Brazil*), and secondly, the Lattes Platform, an integrated database of individual researchers and Brazilian institutions (http://lattes.cnpq.br/), maintained by the Brazilian National Council for Scientific and Technological Development (CNPq). We inspected the Lattes Platform for the leaders of the 19 groups associated with the Brazilian Pharmacogenetics Network (REFARGEN, www.refargen. org.br). Articles were selected from both sources according to the following inclusion criteria: (a) comprise original data; (b) include Brazilian cohorts; (c) published between January 2011 and June 2018; and (d) contain one or more genes covered by the CPIC guidelines. Figure 1 shows a flowchart of our search results. After filtering PubMed entries and publications from REFARGEN members, 72 articles were selected, 22 of which examined both pharmacogene(s) and drug(s) from a CPIC guideline (Table  1 ). The remaining 50 articles investigated one or more genes comprised in the guidelines. We will present our results in the following order: guidelines including genes codifying phase I enzymes (CYP2C19, CYP2D6 CYP3A5 and DPYD), phase II enzymes (TPMT, UGT1A1) and transporters (SLCO1B1), IFNL3, HLA-B haplotypes and lastly, warfarin guidelines, which include genes encoding phase I enzymes (CYP2C9 and CYP4F2) and the drug target (VKORC1).
| RESULTS AND DISCUSSION
For each guideline, we present initially the frequency distribution of the pertinent genetic variants in the Brazilian population. These data are summarized in Table 2 , which shows, whenever available, the variant's frequency in each of the three major segments of the Brazilian population, identified according to the race/colour criterium adopted by the Brazilian Census, namely self-reported white, brown ("Pardo" in Brazilian Portuguese) and black. Otherwise, the overall frequency in Brazilians is shown. Most of the data in Table 2 are derived from a REFARGEN study, in which 1034 healthy individuals were recruited in four geographical regions of the country. 5, 8 These data are accessible at www.refargen.org.br, which also provides data from another REFARGEN study, carried out in collaboration with the Pharmacogenomics Initiative for Every Nation (PGENI), in which 270 Brazilians were genotyped for over 1900 polymorphisms in 215 pharmacogenes, using the DMET platform. 33 Data from this cohort (REFARGEN-PGENI) and other studies were used to complement Table 2 . In different pharmacogenomic contexts, CYP2C19 polymorphisms showed no association with hypersensitivity reactions to anticonvulsants, 35 refractoriness to antipsychotics 36 or conversion of clopidogrel into a carboxylic acid metabolite. 37 Studies from our groups explored other aspects of CYP2C19 pharmacogenetics: firstly, the linkage disequilibrium of CYP2C19*17 with CYP2C8*2 38 ; secondly, the phenoconversion of CYP2C19 activity in patients with visceral leishmaniasis, which was reversible upon treatment with antimonials and/or anfotericin-B 39 ; and thirdly, the ability of aminoglycoside antibiotics to readthrough the stop codon that defines CYP2C19*3, and partially restore CYP2C19 expression and activity. 
| CYP2D6 and tamoxifen
The CPIC recommendations for tamoxifen dosing 41 are based on CYP2D6 phenotypes inferred from CYP2D6 haplotypes, according to the activity score (AS) system. 42 The CYP2D6 haplotypes included in the CPIC guidelines are *1 and *2 (normal function); *3, *4 and *5 (null function); and *9, *10 and *41 (reduced function), as well as duplication or multiplication of gene copies. The distribution of these haplotypes in the REFARGEN cohort does not differ substantially among white, brown and black individuals, although trends for decreasing frequency of haplotypes *4 and *41 from whites to blacks are seen (Table 2) . Friedrich et al 43 adopted the AS system to estimate the distribution of CYP2D6 phenotypes in the REFARGEN cohort: the frequency of poor metabolizers (two non-functional alleles, eg CYP2D6*4/*4) and ultra-rapid metabolizers (multiple gene copies, eg CYP2D6*1/*1xN) in the overall cohort ranged from 2% to 3% and 3% to 5%, respectively. Similar frequencies for inferred CYP2D6 phenotypes were reported for Brazilian breast cancer patients. 13, 24, 44 Antunes and colleagues 45 investigated associations between the plasma concentrations of tamoxifen and metabolites, with CYP2D6 phenotypes, and concluded that "CYP2D6 genotyping and/or phenotyping could not fully predict endoxifen concentrations". The same group confirmed the contribution of CYP3A4 to the bioactivation of tamoxifen and revealed that this "becomes increasingly important in case of reduced or absent CYP2D6 activity". 45 Vianna-Jorge et al 46 published a careful overview of the impact of PGx polymorphisms on the therapy of breast cancer, whereas two other studies examined the frequency of selected CYP2D6 alleles on recurrence, 47 and disease-free survival 48 in Brazilian women with breast cancer. The latter studies included relatively small cohorts (n = 80 and 58, respectively), genotyped limited numbers of known functional CYP2D6 variants and did not examine copy number variation, which collectively compromise the conclusions drawn. The same restrictions apply to the reported "deficiency in tamoxifen metabolism, characterized by intermediate metabolism in 8% of Brazilian women". 49 Other CYP2D6 PGx studies, not related to tamoxifen, confirmed the association of CYP2D6 genotype with increased risk of recurrence of vivax malaria (explained by reduced conversion of the antimalarial pro-drug primaquine into its active metabolites in patients with deficient CYP2D6 enzymatic activity) 50, 51 and failed to support CYP2D6 (and CYP2C19) genotyping as a predictor of therapeutic response to antipsychotics in schizophrenia. 36 
| CYP3A5 and tacrolimus
CPIC guideline for tacrolimus (TAC) 52 is based on genotyping of CYP3A5*3, *6 and *7. The distribution of these alleles in the REFARGEN cohort varies significantly across the major race/colour Brazilian groups (Table 2) . 53, 54 The frequency of allele CYP3A5*3 decreases from white to brown and then to black individuals, whereas the opposite trend is observed for CYP3A5*6 and CYP3A5*7; this is consistent with known differences in individual proportions of African and European ancestry among these groups. 5, 8, 9 Four articles examined CYP3A5 and tacrolimus in a PGx context in Brazilians, and all of them showed association of CYP3A5 genotype with tacrolimus dose-adjusted trough concentrations (TAC Co/dose). 11, 18, 21, 29 The original study by Santoro et al 11 confirmed the impact of CYP3A5*3 on tacrolimus dose requirement, previously described in other populations, and disclosed two novel and important findings: firstly, the association of CYP3A5*6 and CYP3A5*7 with tacrolimus dosing. Secondly, the inclusion of Brazilian patients with the CYP3A5*1/*1 genotype, which is rare or absent in populations of European or Asian descent, allowed demonstration of a gene-dose effect of CYP3A5 polymorphisms on TAC pharmacokinetics. This study provided the basis for inclusion of CYP3A5*6 and *7, in addition to the *3 allele, in the CPIC guideline for tacrolimus. 52 
| DPYD and fluoropyrimidines
The updated CPIC guidelines for DPYD and fluoropyrimidines 55 adopted an activity score system to infer dihydropyrimidine dehydrogenase (DPD) phenotypes, according to four polymorphic sites, namely rs3918290 (DPYD*2A), rs55886062 (DPYD*13) rs67376798 (p.D949V) and rs7501782 (HapB3). The DPYD*2A and *13 alleles were not detected in the REFARGEN-PGENI cohort, 33 while the other two variants (p.D949V and HapB3) were not investigated in this cohort. Another DPYD polymorphism, rs1801159, which the CPIC guideline refers as not affecting "DPD activity in a clinically relevant manner," was reported at a high frequency (25%) in healthy subjects from the North region of Brazil.
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Cunha-Junior et al 17 identified three heterozygous carriers of the deleterious mutations DPYD*2A and 2846A>T among 33 gastrointestinal cancer patients treated with 5-FU, who developed severe, grade 3-4 toxicity. These data corresponded to 100% specificity and 23% specificity for DPYD genotyping to predict 5-FU-induced severe toxicity, which is in good agreement with data from international studies. Cunha-Junior et al also explored the use of 13C-uracyl breath tests to predict 5-FU toxicity and concluded that it has moderate accuracy in discriminating patients susceptible to severe 5-FU toxicity vs mild or no toxicity. 17 Galarza et al 28 compared
DPYD genotyping vs phenotypic methods as predictors of severe fluoropyrimidine toxicity in gastrointestinal tumours and suggested that the ratio of dihydrouracil [UH2] to uracil [U] concentrations in plasma and saliva may be promising functional metrics for predicting fluoropyrimidine toxicity.
| TPMT and thiopurines
The original 2011 57 and the updated 2013 CPIC guidelines 58 for thiopurines are based on genotyping the nonfunctional alleles TPMT*2, *3A, *3B, *3C and *4, and inferred or measured TPMT phenotypes. The combined frequency of alleles TPMT*2, *3A, *3B and *3C in the overall REFARGEN cohort is 4.5%, with similar distribution in self-reported white, brown and black individuals ( Table 2) . These data are consistent with those of previously published studies in Brazilian healthy subjects [59] [60] [61] and in children with acute lymphoblastic leukaemia. 62 No frequency data were found for TPMT*4 in Brazilians.
Our search identified one study of TPMT and thiopurines in a PGx context in Brazilians. Carvalho et al 20 genotyped
TPMT variants in patients with inflammatory bowel disease under treatment with azathioprine. No association was detected regarding myelotoxicity or hepatotoxicity, but a trend towards increased serum levels of pancreatic enzymes was observed in carriers of TPMT*2 and TPMT*3C. PGx testing for TPMT has not been used routinely to guide thiopurine therapy in Brazil. It is likely that the low prevalence of the TPMT poor metabolizer phenotype contributes to the non-adoption of PGx testing for thiopurines. Indeed, poor metabolizers amounted to 0.3% of a Brazilian cohort studied by Reis et al, 59 whereas intermediate and normal metabolizers corresponded to 9.8% and 89.9%, respectively. These proportions are in excellent agreement with the pivotal study of Weinshilboum and Sladek. 
| UGT1A1 and atazanavir
The CPIC guideline for atazanavir 64 considers several polymorphisms in UGT1A1, including a variable dinucleotide (TA) repeat within the gene promoter region (rs8175347, alleles UGT1A1*28, *36 and *37), and the SNPs rs4148323 (UGT1A1*6) and rs887829 (UGT1A1*80). The distribution of the rs8175347 variants and of the rs887829 SNP does not differ across the Brazilian race/colour groups, 65, 66 whereas the UGT1A1*6 allele, common in Asian populations, was not detected in the REFARGEN cohorts ( Table 2) . The association between rs8175347 and adverse reactions to atazanavir was examined in a large cohort of HIV-infected Brazilians. 16 The conclusion was that the UGT1A1*28 allele (seven TA repeats) predisposes to severe hyperbilirubinaemia in individuals under highly active antiretroviral therapy (HAART), especially those exposed to atazanavir. In a different PGx context, UGT1A1 polymorphisms were reported to associate with the L-thyroxine (T 4 ) doses required for thyrotropin suppression following thyroid ablation in patients with differentiated thyroid cancer. 65, 66 The effect size, however, accounted for only 2% of the total variability in T 4 dosage and recommendation of preemptive UGT1A genotyping was deemed not warranted.
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| SLCO1B1 and simvastatin
The 2014 updated CPIC guideline for SLCO1B1 and simvastatin-induced myopathy 67 is based on the common c.521T>C
| RODRIGUES-SOARES AnD SUAREZ-KURTZ variant (rs4149056), contained within SLCO1B1*5, *15 and *17 haplotypes. The frequency distribution of the 521T>C polymorphism in the REFARGEN cohort (Table 2 ) revealed significant, albeit small differences, across the race/colour groups with higher frequency in self-reported whites compared to blacks (Table 2 ). This may be ascribed to the combination of higher frequency of the 521C allele in European (12% in the 1KG Project) compared to African populations (1% in 1KG) and higher proportion of European ancestry in white, compared to black Brazilians. 8, 68 A considerably higher frequency of rs4149056 (28.3%) was detected in native Americans living in the Aracruz Indian Reserve, on the Southeast Brazilian coast. 69 A study examined the association between c.521T>C and two other SNPs in SLCO1B1 (c.388A>G, rs2306283 and c.463C>A, rs11045819), and the simvastatin-induced reduction in low-density lipoprotein (LDL) cholesterol, rather than the drug-induced myopathy. 15 No association was verified between the 521C>T and 463C>A polymorphisms, whereas 388A>G was linked to the simvastatin response, such that a gain of 9% in LDL-C reduction was observed in homozygous 388GG. Similarly, atorvastatin was reported to cause significantly greater LDL-C reduction in patients with the c.388GG genotype compared to carriers of the wildtype allele, whereas the c.521T>C SNP had no influence. 70 Santos et al 71 observed no association of SLCO1B1 haplotypes comprising the c.521T>C and c.388A>G SNPs with atorvastatin-induced myotoxicity in patients with familial hypercholesterolaemia. Brazilian studies of SLCO1B1 genotype in relation to drugs other than statins reported that renal transplant patients carrying the c.388G allele had lower dose adjusted blood concentration of tacrolimus compared to 388AA carriers, while SLCO1B1c.521T>C had no effect 72 and significant interaction between SLCO1B1 genotype and gametocytaemia clearance rate in malaria vivax patients treated with chloroquine and primaquine. 
| IFNL3 and PEG-IFN-α
The CPIC guideline for IFNL3 genotype and pegylated interferon-alpha (PEG-IFN-α)-based regimens in the treatment of hepatitis C virus (HCV) focuses on the rs12979860 (C>T) genotype. 74 The frequency of this SNP in Brazilians is ~40% (Table 2 ). Cavalcante et al 14 examined the association of rs12979860 and the tightly linked rs8099917 (1332A>C) with the outcome of treatment of HCV-1 with PEG-IFN-α and ribavirin. Their results indicated that carrying the variant alleles in heterozygosis or homozygosis was associated with failure to obtain a sustained viral response (SVR) and/ or relapse. These results were verified in another cohort of Brazilian patients 27 and extended to a third polymorphism, namely rs368234815, located upstream to IFNL3 and in extensive linkage disequilibrium with rs12979860. Nastri et al 75 reported that the haplotype G/T/ΔG, comprising the minor alleles at rs8099917, rs12979860 and rs368234815, was related to non-response to PEG-IFN-α-based treatment and to a higher chance of developing chronic infection when compared to the wild-type haplotype T/C/TT.
| HLA-B and abacavir
The CPIC guidelines for the antiretroviral drug, abacavir, first published in 2012 76 and updated in 2014 77 recommend against the use of abacavir in adults and children who test positive for HLA-B*5701. Accordingly, the current guidelines of the Brazilian Ministry of Health (www.aids.gov. br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos) require testing for HLA-B*5701 prior to inclusion of abacavir in antiretroviral combined therapy for HIV infection; the test is available free of cost to users of the Unified Health System. These guidelines recommend association of lamivudine, tenofovir and dolutegravir as the preferential initial anti-HIV therapy, leaving abacavir as an alternative to individuals with counter-indication to tenofovir (eg chronic hepatitis B infection) who tested negative for HLA-B*5701. In Brazilians from the Northeast region, the HLA-B*5701 frequency was reported at 1.5% in HIV-infected patients receiving abacavir treatment and 1.7% in the general population. 78 Importantly, the HLA-B*5701 carriers presented hypersensitivity reaction to abacavir, characterized by cutaneous rash and severe gastrointestinal tract symptoms, which led the authors to emphasize the value of preventive testing for HLA-B*5701 in candidates to abacavir treatment. 
| CYP2C9 and phenytoin
This CPIC guideline for the use of phenytoin 79 is based on CYP2C9*2 and *3 alleles and the HLA-B*1502 haplotype. The frequency of the CYP2C9*2 and CYP2C9*3 ranges from 6.6% to 13.7% and 2.6% to 4.9%, respectively, in the REFARGEN cohort, with trends for decreasing frequency from self-identified white to black individuals (Table 2) , whereas the www.allelefrequencies.net database shows zero frequency HLA-B*1502 in Brazilians.
One study examined the impact of CYP2C9*2 and *3 genotypes on phenytoin adverse reactions and failed to detect an association, possibly because of the small size of the study cohort and the fact that most patients were receiving co-medications. 12 In a small subset of the same cohort, the authors observed a significant reduction in cerebellar white matter volume in carriers of CYP2C9 variants compared to wild-type patients. 80 Other studies of the pharmacogenetics of CYP2C9 in Brazilians will be presented in the following subsection.
| CYP2C9, CYP4F2,
VKORC1 and warfarin
The original CPIC guideline for warfarin 81 was based on CYP2C9*2, CYP2C9*3 and VKORC1 (rs9923231) genotypes, whereas the update released in 2017, 82 included additional polymorphisms in CYP2C9 (alleles *5, *6, *8 and *11), a SNP in CYP4F2 (rs2108622) and SNP rs12777823 in the CYP2C cluster near CYP2C18. A distinct feature of the updated guideline is the incorporation of "recommendations for adult and paediatric patients that are specific to continental ancestry." The frequency distribution of the pertinent CYP2C9, VKORC1 and CYP4F2 polymorphisms among Brazilians (Table 2 ) reveals significant associations with self-reported race/colour and individual proportions of European and/or African ancestry. [83] [84] [85] Of notice, the frequency of CYP2C9*2, CYP2C9*3 and VKORC1 rs9923231 allele A, which are major determinants of warfarin dosing requirements, as well as CYP4F2 rs2108622 allele T, decreases progressively, and significantly, as the individual proportion of African ancestry increases. The distribution of CYP2C9, VKORC1 and CYP4F2 SNPs among native populations living in Brazil has also been reported. 86 We found no frequency data for rs12777823.
The PGx of warfarin has been investigated in several studies of Brazilian patients. Despite the availability of the new oral anticoagulants (NOAC) in Brazil, warfarin continues to be widely used and, indeed, the National Commission for the incorporation of novel technologies in the Brazilian Unified Health System recommended "non-incorporation of the drugs apixaban, rivaroxaban and dabigatran for the prevention of cerebrovascular accident in patients with chronic non-valvular atrial fibrillation" (http://conitec.gov.br/images/ Relatorios/Report/Report195_2016.pdf). Prior to the original CPIC warfarin guideline, Suarez-Kurtz and collaborators 87, 88 developed and validated PGx algorithms for warfarin dosing, which explained 51%-60% of the variability in stable dose requirement and, most importantly, performed equally well in self-reported white and black individuals. The latter finding contrasts markedly with the considerably poorer performance of warfarin algorithms in African Americans vs white Americans, 89 which is not reversed by inclusion of a "race" term in the algorithms. 89, 90 This discrepancy was ascribed to the marked difference in frequency of the relevant VKORC1 and CYP2C9 SNPs between black Brazilians and AfricanAmericans or black Africans. 8, 9, 87 In subsequent studies, other PGx dosing algorithms have been proposed: Botton et al 10 developed two dosing algorithms, comprising PGx polymorphisms in VKORC1, CYP2C9 and CYP4F2, clinical, demographic and medication covariates. The predictive power of these algorithms, R 2 = 0.58-0.63, is among the highest reported in the literature. A considerably poorer performance was described for another PGx algorithm based on VKORC1 and CYP2C9 polymorphisms. 26 In separate publications, the same group concluded that "genetic information on CYP2C9 and VKORC1 is important both for the initial dose-finding phase and during maintenance treatment with warfarin", 19 "amiodarone influences warfarin maintenance dose" while not being associated with adverse events 23 and CYP4F2 rs2108622 has no effect of warfarin dose requirements in their patients, whereas the ABCB1 c.3435T allele marginally affected the dose requirements. 91 The direction of the latter effect was opposite to previously reported higher warfarin dose requirement in thrombophilic patients with the ABCB1 c.3435T allele. 22, 92 A recent study concluded that ABCB1 and CYP4F2 polymorphisms improve by 2.6% the coefficient of determination of warfarin dosing algorithms. 32 Differences in study design and/or characteristics of the cohorts may account for discrepancies in the perceived impact of CYP4F2 and ABCB1 polymorphisms on warfarin dose requirement. A genomewide association study (GWAS) 25 93 The results revealed differential effects of CYP2C9*2 allele, simvastatin use and possession of a prosthetic heart valve. 31 However, the accuracy of race/colour-stratified warfarin dosing algorithms for white and black patients was not superior to the non-stratified algorithm derived previously from the same cohort. 87 interaction between warfarin and simvastatin in Swedish patients. 96 PGx studies of CYP2C9, not related to anticoagulants, explored associations with the antimalarial effect of chloroquine/primaquine therapy 97 and the efficacy of piroxicam for post-operative pain, 98 with negative results in both cases.
| CONCLUSIONS
The present survey suggests that adoption of PGx-guided prescription in Brazil has been sporadic. This is the likely result of a combination of factors, some specific to Brazil and the structure of the Brazilian population, and others that are recognized as barriers to implementation of PGx-informed prescription worldwide. Specific factors comprise the very low frequency or absence in Brazilians of genetic variants which guide the recommendations for PGx-informed prescription in the CPIC and other international guidelines (eg HLA-B*15.02 for phenytoin and carbamazepine), and, conversely, the non-inclusion in the guidelines of variants that are relevant to Brazilians. For example, the original CPIC guideline for warfarin 81 was based on the CYP2C9*2 and CYP2C9*3 alleles, which do not cover the extent of CYP2C9 polymorphism in populations of African descent, such as admixed Brazilians. The updated CPIC guideline 82 incorporated variants that are more frequent in African-derived populations and, importantly, provided dosing recommendations for warfarin "that are specific for continental ancestry." Nevertheless, continental ancestry in admixed populations is not a categorical, but rather a continuous variable, even within self-reported race/colour categories. 5, 8, 9 This pattern of continuous variation in ancestry proportions, evident in Figure  S1 , based on data from a GWAS of warfarin in Brazilians, 25 is a caveat to implementation of guidelines based on continental ancestry-as well as "race" or ethnicity-in Brazil, and most likely other admixed populations in Latin America. Recognition of this fact should be an incentive to develop "local" guidelines or adapt existing guidelines for PGx-informed drug prescription, according to the population structure and clinical practice of the target country or region. Recognized barriers to adoption of PGx-informed prescription worldwide 1 are also verified in Brazil, such as minimal or no insertion of PGx teaching in medical and pharmacy curricula, limited availability of PGx tests, no reimbursement for PGx tests by private insurance providers and lack of cost-effectiveness analyses based on current health costs in Brazil. A project, with financial support from the Brazilian Ministry of Health and the National Research Council (CNPq), is currently under way, led by one of us (GS-K) to develop standard operational procedures towards implementation of PGx tests in unities of the Brazilian Unified Health System.
